Skip Navigation


JAC Advance Access originally published online on February 22, 2005
Journal of Antimicrobial Chemotherapy 2005 55(4):410-412; doi:10.1093/jac/dki038
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/4/410    most recent
dki038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Noë, A.
Right arrow Articles by Verhofstede, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noë, A.
Right arrow Articles by Verhofstede, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Leading article

The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance

Ann Noë, Jean Plum and Chris Verhofstede*

AIDS Reference Laboratory, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium

* Corresponding author. Tel: +32-9-240-51-61; Fax: +32-9-240-36-59; Email: chris.verhofstede{at}ugent.be

Recent studies on patients with a history of pre-HAART drug resistance, but currently on a successful regimen, provided new insights into the dynamics of the latent cellular viral reservoir. Results indicated that the latent reservoir is an archive, composed of a mixture of wild-type and drug-resistant strains. The studies showed that, even after years of successful HAART, the wild-type viral strains that circulated before the initiation of the therapy as well as all the different drug-resistant viral strains that evolved over time during eventual periods of non-suppressive treatment, remain detectable in the proviral reservoir. These findings support the hypothesis that during active viral replication, new variants, including drug-resistant ones, continuously enter the latent viral reservoir. It can be concluded that, as a consequence of the lifelong conservation of this latent reservoir, the potency of drugs for which resistance once developed will remain reduced, even after years of withdrawal of the drug.

Keywords: reservoirs of resistance , mechanisms of resistance , mutations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
D. Hoffmann, J. Seebach, A. Cosma, F. D. Goebel, K. Strimmer, H. M. Schatzl, and V. Erfle
Therapeutic vaccination reduces HIV sequence variability
FASEB J, February 1, 2008; 22(2): 437 - 444.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. Steegen, S. Luchters, E. Demecheleer, K. Dauwe, K. Mandaliya, W. Jaoko, J. Plum, M. Temmerman, and C. Verhofstede
Feasibility of Detecting Human Immunodeficiency Virus Type 1 Drug Resistance in DNA Extracted from Whole Blood or Dried Blood Spots
J. Clin. Microbiol., October 1, 2007; 45(10): 3342 - 3351.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.